@article{b235a84e47ba4018be812da0eb150e47,
title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy",
abstract = "Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).",
author = "B. Moriyama and Obeng, {A. Owusu} and J. Barbarino and Penzak, {S. R.} and Henning, {S. A.} and Scott, {S. A.} and Ag{\'u}ndez, {J. A.G.} and Wingard, {J. R.} and McLeod, {H. L.} and Klein, {T. E.} and Cross, {S. J.} and Caudle, {K. E.} and Walsh, {T. J.}",
note = "Funding Information: T.J.W. is a Scholar of the Sharp Family Foundation in Pediatric Infectious Diseases and an Investigator of Emerging Infectious Diseases of the Save Our Sick Kids Foundation. The members of CPIC and the CPIC Informatics Working Group are acknowledged for their support in this project. All members are listed online at: https://cpicpgx.org/members/. We acknowledge the critical input of Dr Mary V. Relling (St Jude Children{\textquoteright}s Research Hospital) and Dr Andrea Gaedigk (Children{\textquoteright}s Mercy Kansas City). This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264) and PharmGKB (R24GM61374). A.O.O. is supported in part by the NIH/NHGRI (U01HG006380). S.A.S. is supported in part by the National Institute of General Medical Sciences (NIGMS) of the NIH, through grant K23GM104401. J.A.G.A. acknowledges financial support from RD12/0013/0002; ISCIII and FEDER. Funding Information: T.J.W. is a Scholar of the Sharp Family Foundation in Pediatric Infectious Diseases and an Investigator of Emerging Infectious Diseases of the Save Our Sick Kids Foundation. The members of CPIC and the CPIC Informatics Working Group are acknowledged for their support in this project. All members are listed online at: https://cpicpgx.org/members/. We acknowledge the critical input of Dr Mary V. Relling (St Jude Children's Research Hospital) and Dr Andrea Gaedigk (Children's Mercy Kansas City). This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264) and PharmGKB (R24GM61374). A.O.O. is supported in part by the NIH/NHGRI (U01HG006380). S.A.S. is supported in part by the National Institute of General Medical Sciences (NIGMS) of the NIH, through grant K23GM104401. J.A.G.A. acknowledges financial support from RD12/0013/0002; ISCIII and FEDER. Publisher Copyright: {\textcopyright} 2016 American Society for Clinical Pharmacology and Therapeutics",
year = "2017",
month = jul,
day = "1",
doi = "10.1002/cpt.583",
language = "English",
volume = "102",
pages = "45--51",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Wiley-Blackwell",
number = "1",
}